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An adequate protocol for antimicrobial prophylaxis (AMP) in radical prostatectomy (RP) has not been
established. We retrospectively compared the occurrence of perioperative infection following RP between two
different AMP protocols. This study included 340 cases with prostate cancer who underwent RP at our
institution between January 2005 and December 2008. The 1-day group consisting of 93 cases received a
second generation cephem, cefotiam, intravenously during and after the operation on the operative day. The
single dose group consisting of 247 cases received cefotiam during the operation only. The incidence of
surgical site infection (SSI）and remote infection (RI) was retrospectively investigated. There was no
significant difference in the rate of SSI and RI occurrence between the 1-day group (2.2, 0%) and single dose
group (3.6, 0.4%) (p＝0.52). The single dose protocol of AMP seems sufficient for prevention of
perioperative infection in RP.
(Hinyokika Kiyo 56 : 559-563, 2010)














対 象 と 方 法
2005年 1月から2008年12月に当院にて RP を施行し
た340名を対象とし，抗菌薬の術中投与に帰室後単回
投与を加えた 1 日投与群 (n＝93，2005/1∼2006/1)
と，術中投与に限った単回投与群 (n＝247，2006/2∼
2008/12) に分類した．手術部位感染 (surgical site












して Cefotiam (1 g) を選択し，経静脈投与した．その
術中の投与法は，皮切開始までに初回投与を完了させ
たのち， 3時間ごとに追加投与した．また，周術期感
染症の判定には，CDC (Centers for Disease Control and
Prevention) の定義2)を用いた．
統計学的判定には， Statistical Package for Social
Sciences version 14.0 (SPSS，Chicago，IL) を用いて
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有意に短かった (p＜0.0001）．RP 前の平均 PSA は両
群共に 9 ng/ml 前後で，有意差を認めなかった．全割
標本の検討において，Tステージの割合やリンパ節転
移陽性率，Gleason score を対象とした 2群間の比較に
て，有意差を認めなかった (Table 1）．
単回投与群の SSI と RI 発生率は，おのおの3.6％

















Table 1. Clinical characteristics
1-day group (n＝93) Single dose group (n＝247) p-value
Age (years) 66.9±5.2 66.7±5.9 p＝0.86
BMI ≦24.9 (kg/m2) 58 (62.4) 162 (65.6)
｝p＝0.5825.0-29.9 33 (35.5) 80 (32.4)
≧30.0 2 ( 2.1) 5 ( 2.0)
Diabetes mellitus 11 (11.8) 22 ( 8.9) p＝0.42
Hypertension 31 (33.3) 86 (34.8) p＝0.80
Anticoagulant drugs 7 ( 7.5) 28 (11.3) p＝0.30
Preoperative UTI 2 ( 2.2) 9 ( 3.6) p＝0.49
Operation time (min) 242±42 218±39 p＜0.0001
Blood loss (ml) 1,344±885 1,106±805 p＝0.0025
Blood transfusion 6 ( 6.5) 11 ( 4.5) p＝0.45
Hospital discharge (POD) 10.5±2.2 9.8±4.0 p＜0.0001
Initial-PSA (ng/ml) 8.5±5.4 9.4±7.6 p＝0.81
pT stage ≦T2c 82 (88.1) 206 (83.4)
｝p＝0.28T3a, b 11 (11.9) 41 (16.6)
LN metastasis 1 ( 1.1) 3 (1.2) p＞0.99
Gleason score ≦6 29 (31.2) 56 (22.7)
｝p＝0.17＝7 49 (52.7) 134 (54.2)≧8 15 (16.1) 57 (23.1)
Data are presented as mean±SD or number (％). BMI, body mass index ; UTI, urinary tract
infection ; POD, post operative day ; PSA, prostate-specific antigen ; LN, lymph node.
Table 2. Occurrence of SSI and RI
1-day group (n＝93) Single dose group (n＝247) p-value
Surgical site infection 2 (2.2) 9 (3.6) p＝0.73
Superficial incisional 2 (2.2) 5 (2.0)
｝p＝0.68Deep incisional 0 (0 ) 1 (0.4)Organ/space 0 (0 ) 3 (1.2)
Remote infection 0 (0 ) 1 (0.4) p＝0.99
Total 2 (2.2) 10 (4.0) p＝0.52
Data are presented as number (％).
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していた (p＝0.04）．一方，感染症が皮下に留まる群
では，非発症群と比べて，術後の体温や白血球数，









る．一方で，本邦における RP に関連した SSI や RI
の発生率は 5％前後と報告されている1,4~9) (Table
5）．われわれの検討において，抗菌薬を術中投与に



















Table 3. Relationship between SSI / RI positive and negative with baseline and
perioperative characteristics
SSI/RI (−) (n＝237) SSI/RI (＋) (n＝10) p-value
Age (years) 66.7±6.0 65.0±4.6 p＝0.56
BMI (kg/m2) 24.0±2.6 24.4±5.2 p＝0.95
Diabetes mellitus 21 ( 8.9) 1 (10.0) p＝0.90
Hypertension 80 (33.8) 6 (60.0) p＝0.10
Anticoagulant drugs 26 (11.0) 2 (20.0) p＝0.32
Preoperative UTI 8 ( 3.4) 1 (10.0) p＝0.31
Operation time (min) 218±39 224±43 p＝0.79
Blood loss (ml) 1,101±808 1,215±755 p＝0.73
Blood transfusion 11 ( 4.6) 0 ( 0.0) p＝0.99
Drain removal (POD) 3.9±1.3 7.6±5.9 p＝0.002
Catheter removal (POD) 7.9±3.6 9.2±3.6 p＝0.19
Data are presented as mean±SD or number (％). BMI, body mass index ; UTI, urinary tract
infection ; POD, post operative day.
Table 4. Postoperative change in body temperature and laboratory data
SSI/RI (−) (n＝237) s-SSI* (n＝5) p-value*** d-SSI**＋RI (n＝5) p-value****
Highest Body Temperature (°C)
POD 1 37.4±0.5 37.3±0.5 p＝0.55 37.2±0.4 p＝0.40
POD 2 37.2±0.5 37.2±0.5 p＝0.81 37.1±0.4 p＝0.61
POD 3 36.8±0.5 36.6±0.7 p＝0.35 37.2±0.4 p＝0.17
POD 4 36.6±0.5 36.8±0.6 p＝0.50 37.0±0.4 p＝0.11
POD 5 36.5±0.5 36.6±0.3 p＝0.31 37.2±0.6 p＝0.04
Leucocyte counts (×103/μl)
POD 1 8.1±1.9 6.5±1.3 p＝0.17 10.0±2.4 p＝0.06
POD 3 7.2±1.8 6.0±1.4 p＝0.51 9.0±7.0 p＝0.04
C-reactive protein (mg/dl)
POD 1 3.4±1.4 2.2±0.9 p＝0.06 3.2±1.7 p＝0.80
POD 3 6.1±2.3 2.8±1.2 p＝0.01 6.1±1.9 p＝0.98
Data are presented as mean±SD ; * s-SSI, Superficial incisional SSI ; ** d-SSI, Deep incisional SSI＋Organ/Space SSI ; *** p-value,
s-SSI group vs SSI/RI (−) group ; **** p-value, d-SSI＋RI group vs SSI/RI (−) group ; POD, post operative day.
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縮化なども積極的に行っている．その結果，リスク因
子と認知されている肥満や高齢，糖尿病なども，当院




































1) Terai A, Ichioka K, Inoue K, et al. : Antibiotic
prophylaxis in radical prostatectomy : 1-day versus 4-
day treatments. Int J Urol 13 : 1488-1493, 2006
2) Mangram AJ, Horan TC, Pearson ML, et al. :
Guideline for prevention of surgical site infection,
1999. Infect Control Hosp Epidemiol 20 : 247-278,
1999
3) Hecker MT, Aron DC, Patel NP, et al. : Unnecessary
use of antimicrobials in hospitalized patients : current
patterns of misuse with an emphasis on the anti-
anaerobic spectrum of activity. Arch Intern Med
163 : 972-978, 2003
4) Arai Y, Egawa S, Tobisu K, et al. : Radical retropubic
prostatectomy : time trends, morbidity and mortality in
Japan. BJU Int 85 : 287-294, 2000
5) 田所 学，増田 均，奥野哲男，ほか : ミニマム
創・内視鏡下泌尿器手術における手術部位感染の
臨床的検討．泌尿紀要 49 : 721-725，2003
6) 山本新吾，国島康晴，金丸聰淳，ほか : 泌尿器科
領域における周術期感染症阻止薬適正使用に関す
る多施設共同研究．泌尿紀要 50 : 673-683，2004
7) 田中雅博，藤本清秀，三宅牧人，ほか : 泌尿器科
領域における周術期感染症．泌尿器外科 19 :
523-530，2006
8) Takeyama K, Takahashi S, Maeda T, et al. :
Comparison of 1-day, 2-day, and 3-day administration
of antimicrobial prophylaxia in radical prostatectomy.
J Infect Chemother 13 : 320-323, 2007
9) Sakura M, Kawakami S, Yoshida S, et al. : Prospective
comparative study of single dose versus 3-day admini-
stration of antimicrobial prophylaxis in minimum
incision endscopic radical prostatectomy. Int J Urol
Table 5. Recent reports on perioperative infectious complications and antibiotic prophylaxis protocol
Author year Antimicrobials Duration No. pts SSI [n (％)] RI [n (％)]
Arai et al.4) 2000 Not stated 638 48 ( 7.5) Not stated
Tadokoro et al.5) 2003 2nd cephems 2-4 days 36 1 (2 .8) Not stated
Yamamoto et al.6) 2004 Penicillins 3 days 85 0 (0 ) 7 (8.3)
1st cephems 3 days 116 4 ( 3.4) 9 (7.8)
2nd cephems 3 days 120 15 (12.5) 8 (6.7)
Tanaka et al.7) 2006 1st-3rd cephems 3, 4 days 55 5 ( 9.1) 2 (3.6)
Terai et al.1) 2006 2nd cephems 4 days 50 0 ( 0 ) 0 (0 )
1 day 81 1 ( 1.2) 0 (0 )
Takeyama et al.8) 2007 2nd cephems Single 19 1 ( 5.2) 1 (5.2)
Sakura et al.9) 2008 Penicillins Single 49 3 ( 6.1) 1 (2.0)
Present study Cefotiam Single 247 9 ( 3.6) 1 (0.4)
泌尿紀要 56巻 10号 2010年562
15 : 328-331, 2008
10) Naber KG, Bergman BM Bishop MC, et al. : EAU
guideline for the management of urinary and male
genital tract infection. Eur Urol 40 : 476-588, 2001
11) Grabe M, Bishop MC, Bjerklund-Johansen TE, et al. :
Guidelines on the management of urinary and male
genital tract infection. http:// www. uroweb. org/
fileadmin/ tx_eauguidelines/ 2009/ Full/ Urological_
Infections.pdf, 2009
12) 松本哲朗，山本新吾，荒川創一，ほか : 泌尿器科
領域における周術期感染予防ガイドライン．日泌
尿会誌 97 : np1-np2，1-35，2006
13) Wolf JS, Bennett CJ, Dmochowski RR, et al. : Best
practice policy statement on urologic surgery anti-
microbial prophylaxis. J Urol 179 : 1379-1390, 2008
(
Received on March 23, 2010
)Accepted on June 26, 2010
田岡，ほか : 前立腺全摘除術・周術期感染症・抗菌薬 563
